Status:
TERMINATED
RGD-PET-CT in Cancer Angiogenesis
Lead Sponsor:
Oxford University Hospitals NHS Trust
Collaborating Sponsors:
GE Healthcare
University of Oxford
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical research study is to look at 2 new methods of scanning and see whether they can help researchers predict which tumours will respond to drugs that attack tumour blood supply.
Eligibility Criteria
Inclusion
- Patients should have advanced or metastatic RCC confirmed by histological diagnosis
- Patients considered suitable for therapy with TKI for RCC according to responsible clinician
- Measurable tumour according to RECIST v1.1 criteria
- Standard staging CT scan performed within 28 days of first research scan
- The patient has not received chemotherapy, radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to recruitment
- Age ≥18 years
- Adequate renal function (creatinine \<1.25xULN)
- Patient is able to tolerate and comply with scanning procedure
- Patient is not lactating or pregnant
- Absence of any psychological, familial, sociological or geographical condition which in the opinion of the Investigator may potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Able and willing to give informed consent
Exclusion
- Not applicable
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01492192
Start Date
May 1 2013
End Date
September 1 2015
Last Update
November 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiology, Oxford University Hospitals NHS Trust
Oxford, Oxfordshire, United Kingdom, OX3 7LJ